Terms: = Uterine cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Diagnosis
12 results:
1. LncRNA MAGI2-As3 Suppresses the Proliferation and Invasion of Cervical cancer by Sponging MiR-15b.
Chai Y; Wang L; Qu Y; Hu Z
J Healthc Eng; 2022; 2022():9707206. PubMed ID: 35126958
[TBL] [Abstract] [Full Text] [Related]
2. Adipocyte related peptides - galanin and resistin in endometrioid type endometrium cancer.
Nergiz Avcıoğlu S; Yüksel H
Ginekol Pol; 2022; 93(12):941-947. PubMed ID: 35072231
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small cancer Panel.
Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
[TBL] [Abstract] [Full Text] [Related]
4. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
5. In vivo optical cellular diagnosis for uterine cervical or vaginal intraepithelial neoplasia using flexible gastrointestinal endocytoscopy -a prospective pilot study.
Ono S; Nozaki A; Matsuda K; Takakuwa E; Sakamoto N; Watari H
BMC Cancer; 2020 Oct; 20(1):955. PubMed ID: 33008349
[TBL] [Abstract] [Full Text] [Related]
6. Cost of care for the initial management of cervical cancer in women with commercial insurance.
Blanco M; Chen L; Melamed A; Tergas AI; Khoury-Collado F; Hou JY; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2021 Mar; 224(3):286.e1-286.e11. PubMed ID: 32818476
[TBL] [Abstract] [Full Text] [Related]
7. Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study.
Segondy M; Kelly H; Magooa MP; Djigma F; Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Michelow P; Doutre S; Clavero O; Chikandiwa A; Sawadogo B; Didelot MN; Costes V; Méda N; Delany-Moretlwe S; Mayaud P
Br J Cancer; 2016 Aug; 115(4):425-30. PubMed ID: 27434037
[TBL] [Abstract] [Full Text] [Related]
8. Compliance with cervical cancer screening and human papillomavirus testing guidelines among insured young women.
Hirth JM; Tan A; Wilkinson GS; Berenson AB
Am J Obstet Gynecol; 2013 Sep; 209(3):200.e1-7. PubMed ID: 23727519
[TBL] [Abstract] [Full Text] [Related]
9. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.
Singh H; Demers AA; Nugent Z; Mahmud SM; Kliewer EV; Bernstein CN
Gastroenterology; 2009 Feb; 136(2):451-8. PubMed ID: 18996382
[TBL] [Abstract] [Full Text] [Related]
10. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract] [Full Text] [Related]
11. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
[TBL] [Abstract] [Full Text] [Related]
12. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers.
Chu J; Schweid AI; Weiss NS
Am J Obstet Gynecol; 1982 Jul; 143(5):569-73. PubMed ID: 7091228
[TBL] [Abstract] [Full Text] [Related]
